已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

免疫原性 医学 2019年冠状病毒病(COVID-19) 病毒学 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 2019-20冠状病毒爆发 计算生物学 生物 免疫学 爆发 抗原 内科学 传染病(医学专业) 疾病
作者
Edward E. Walsh,Robert W. Frenck,Ann Regina Falsey,Nicholas R.E. Kitchin,Judith Absalon,Alejandra Gurtman,Stephen P. Lockhart,Kathleen Maletic Neuzil,Mark J. Mulligan,Ruth E. Bailey,Kena A. Swanson,Ping Li,Kenneth J. Koury,Warren V. Kalina,David Cooper,Camila R. Fontes-Garfias,Pei‐Yong Shi,Özlem Türeci,Kristin R. Tompkins,Kirsten E. Lyke
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:383 (25): 2439-2450 被引量:2748
标识
DOI:10.1056/nejmoa2027906
摘要

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is currently available. Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States. METHODS: In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States, we randomly assigned healthy adults 18 to 55 years of age and those 65 to 85 years of age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain; or BNT162b2, which encodes a membrane-anchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation. The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome. Trial groups were defined according to vaccine candidate, age of the participants, and vaccine dose level (10 μg, 20 μg, 30 μg, and 100 μg). In all groups but one, participants received two doses, with a 21-day interval between doses; in one group (100 μg of BNT162b1), participants received one dose. RESULTS: A total of 195 participants underwent randomization. In each of 13 groups of 15 participants, 12 participants received vaccine and 3 received placebo. BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults. In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers, which were similar to or higher than the geometric mean titer of a panel of SARS-CoV-2 convalescent serum samples. CONCLUSIONS: The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
maplesirup发布了新的文献求助30
1秒前
韦我完成签到 ,获得积分10
2秒前
陈翊完成签到 ,获得积分10
3秒前
4秒前
Lucas的应助被你爱吃鱼吗采纳,获得10
4秒前
科目三的应助被kk采纳,获得10
5秒前
syvshc的应助被kk采纳,获得10
5秒前
期许完成签到,获得积分10
5秒前
reaaa完成签到 ,获得积分10
6秒前
Jerry的应助被shaangu623采纳,获得30
6秒前
琪琪完成签到,获得积分10
6秒前
愉快的朝雪完成签到,获得积分10
6秒前
SheltonYang发布了新的文献求助30
6秒前
7秒前
米线儿完成签到,获得积分10
8秒前
毒药完成签到 ,获得积分10
8秒前
初椿完成签到 ,获得积分10
8秒前
勤奋成威完成签到,获得积分10
8秒前
阳光暖暖的完成签到 ,获得积分10
10秒前
星星完成签到,获得积分10
10秒前
小李完成签到 ,获得积分10
10秒前
哈人发布了新的文献求助10
10秒前
Tao完成签到 ,获得积分10
10秒前
NN的应助被HUANG采纳,获得10
10秒前
希望天下0贩的0的应助被HUANG采纳,获得10
10秒前
mmm完成签到,获得积分20
11秒前
风中的香寒完成签到 ,获得积分10
11秒前
小老屁发布了新的文献求助30
11秒前
11秒前
shaangu623完成签到,获得积分20
11秒前
Cakoibao的应助被科研通管家采纳,获得10
12秒前
无花果的应助被科研通管家采纳,获得10
12秒前
入司的应助被科研通管家采纳,获得10
12秒前
852的应助被科研通管家采纳,获得10
12秒前
12A完成签到,获得积分10
12秒前
汉堡包的应助被科研通管家采纳,获得10
12秒前
12秒前
Orange的应助被科研通管家采纳,获得10
12秒前
哈哈哈发布了新的文献求助30
13秒前
乐乐的应助被期许采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194810
求助须知:如何正确求助?哪些是违规求助? 9580525
关于积分的说明 21871483
捐赠科研通 7794329
什么是DOI,文献DOI怎么找? 3437718
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484446